C4 Therapeutics, Inc. (CCCC) Misses Q3 EPS by 3c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q3 EPS of ($0.44), $0.03 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $11.23 million versus the consensus estimate of $6.13 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Craig-Hallum Upgrades Backblaze Inc (BLZE) to Buy
• Italy's Meloni seeks to normalize US relations after Trump spat